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Abstract: Glioblastoma (GBM) is among the deadliest of solid tumors with median survival rates
of approximately 12–15 months despite maximal therapeutic intervention. A rare population of
self-renewing cells referred to as GBM cancer stem-like cells (GSCs) are believed to be the source
of inevitable recurrence in GBM. GSCs exhibit preferential activation of the DNA damage response
pathway (DDR) and evade ionizing radiation (IR) therapy by superior execution of DNA repair
compared to their differentiated counterparts, differentiated GBM cells (DGCs). Replication Protein A
(RPA) plays a central role in most of the DNA metabolic processes essential for genomic stability,
including DNA repair. Here, we show that RPA is preferentially expressed by GSCs and high RPA
expression informs poor glioma patient survival. RPA loss either by shRNA-mediated silencing or
chemical inhibition impairs GSCs’ survival and self-renewal and most importantly, sensitizes these
cells to IR. This newly uncovered role of RPA in GSCs supports its potential clinical significance as a
druggable biomarker in GBM.
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1. Introduction
A key feature that distinquishes cancer cells from most normal cells is their sustained proliferation.
Faithful replication and segregation of DNA material into daugther cells is therefore fundamental to
genome stability and cell survival. Seminal studies have shown that pre-cancerous lesions display
baseline DNA damage, supposedly caused by unscheduled replication initiation upon oncogenic
stimuli [1]. Replication stress (RS) occurs when replication forks encounter aberrant DNA structures,
which either stall, block or prematurely terminate their progression, ultimately causing fork collapse
and the formation of long stretches of single-stranded DNA (ssDNA) [1,2]. ssDNA is bound with
replication protein A (RPA), a heterotrimeric protein composed of three subunits, RPA14, RPA32 and
RPA70. Although a correlation between RS and genomic instability is well acknowledged, molecular
mechanisms underpinning this coupling remain elusive [2–4]. Glioblastoma (GBM, a World Health
Organization/WHO grade IV glioma) is among the deadliest of solid tumors with median survival
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rates of approximately 12–15 months despite maximal therapeutic intervention [5]. Rampant genomic
instability and radio-resistance are among the hallmarks of GBM. A population of theraputically
resistant self-renewing cancer stem-like cells (CSCs) stands at the apex of celullar hierarchies found
in these aggressive heterogenous tumors. In GBM, the CSCs (GBM cancer stem-like cells; GSCs),
prospectively isolated based on the expression of cell surface makers such as CD133, exhibit superior
DNA repair capacity, which protect them from the impact of genotoxic therapies such as ionizing
radiation (IR) or chemotherapy by alkylating agent temozolomide [6–9]. IR, a standard of care for GBM,
induces a plethora of DNA lesions, including oxidative base damages, ssDNA breaks and double-strand
breaks (DSBs). In response to such DNA damage, a network of events collectively termed as the
DNA damage response pathway (DDR) is activated and includes DNA damage recognition, activation
of check-points, cell cycle arrest and ultimately cell death [2,10]. DDR is primarily coordinated by
two signaling cascades: ataxia telaniectasia mutated (ATM)-checkpoint kinase 2 (CHK2) pathway
and ataxia telengiectasia and Rad3-related (ATR)-checkpoint kinase 1 (CHK1) pathway, of which
the activation then results in the phosphorylation of H2AX at Ser139 (H2AX), a marker for the
double-strand DNA breaks (DSBs) [11]. Upon DNA damage or RS, the activation of these pathways
leads to hyperphosphorylation of RPA, which modulates its role in response to various genotoxic
insults [3].
A central challenge of IR therapy is to maximize the cancer cell eradication while minimizing the
impact on healthy tissues. Thus, targeting factors dispensable for normal but essential for cancer cells to
evade the consequences of genotoxic insults may help us to enhance the efficacy of IR whilst minimizing
side effects on normal brain parenchyma [12]. In this study, we show that RPA is preferentially expressed
by the radio-resistant pool of GSCs. RPA loss impairs the survival and self-renewing potential of GSCs
while driving them into cell death by apoptosis. Most importantly, both silencing by shRNA and
chemical inhibition of RPA by (1Z)-1-[(2-Hydroxyanilino)methylidene]naphthalen-2-one (HAMNO)
induce DSBs, a challenge that impairs the DNA repair capacity of GSCs, ultimately increasing their
sensitivity to IR.
2. Results
2.1. RPA is Overexpressed in High-Grade Gliomas and Informs Patient Survival
Previous studies have implied that RS is an early event in the formation of GBM [13]. Since
the heterotrimeric protein RPA is among the first responders to RS and by its interaction with ATR
mediates the activation of DDR [3], we sought to examine its expression in a cohort of GBM patients
and compared it to that of heatlhy controls. We chose the publicaly available REMBRANDT and
The Cancer Genome Atlas (TCGA) glioma data sets and interrogated the expression of all three RPA
subunits, RPA70, RPA32 and RPA14, using the gliovis platform (http://gliovis.bioinfo.cnio.es/,visited on
12/02/2020) [14]. As shown in Figure 1A, Supplementary Figure S1A, all three RPA subunits RPA70,
RPA32 and RPA14 were expressed at higher levels in GBM compared to normal brain (NB) controls.
Moreover, RPA was overexpressed in high-grade gliomas (Word Health Organization, WHO grade
III and IV) compared to low grade lesions (WHO grade II) (Figure 1B, Supplementary Figure S1B).
The Kaplan-Meier survival analysis revealed that low RPA70, RPA32 and RPA14 expression associates
with a better prognosis of glioma patients (Figure 1C, Supplementary Figure S1C). When assessing
the impact of RPA expression on the survival of GBM patients only, Kaplan-Meier survival analysis
showed that high expresion of RPA70 and RPA14, but not RPA32, informs worse patient survival
(Supplementary Figure S2A). A multivariate Cox proportional hazard regression analysis of the TCGA
data sets (see Supplementary Figure S2B and Supplementary Tables S1 and S2) showed that only RPA14
expression in low-grade gliomas could serve as an independent prognostic factor. The prognostic value
of RPA70 and RPA32 expression is dependent on other prognostic factors such as WHO grade, age and
isocitrate dehydrogenase (IDH) status in both low- and high-grade gliomas (see Supplementary Figure
S2B and Supplementary Tables S1 and S2).
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Figure 1. Replication protein A (RPA) is overexpressed in high-grade gliomas and informs patient
survival. (A) RPA70, RPA32, RPA14 expression analysis of REMBRANDT data (the National Cancer
Institute’s repository) comparing glioblastoma (GBM) and normal brain (NB) controls. (B) RPA70,
RPA32, RPA14 expression analysis of REMBRANDT data (the National Cancer Institute’s repository)
comparing WHO grade II, III and IV gliomas. Statistical significance was tested using Tukey’s honestly
significant difference test, HSD. ns: not significant; ** p < 0.01; *** p < 0.001. (C) Kaplan-Meier survival
analysis of REMBRANDT glioma data set shows that high RPA expression (all subunits) informs poor
patient prognosis.
2.2. RPA Expression is Crucial for the Maintenance of Glioblastoma Cancer Stem-Like Cells
Our previous work has shown that gliomas, in general, and GSCs, in particular, exhibit high
reactive oxygen species (ROS) production and with that associated high baseline of oxidative DNA
damage, which leads to the accumulation of ssDNA [13–15]. Since RPA coats ssDNA immediately
upon its inception, we sought to investigate the RPA protein expression in patient-derived primary
cell cultures passed as mouse xenografts. On immunoblot, all three RPA subunits were expressed
at higher levels in our collection of primary GBM cell lines compared to normal human astrocytes
(NHA33 and NHA26; Figure 2A). Next, we assessed the RPA expression in acutely dissociated
and Magnetic-Activated Cell Sorting (MACS) -sorted matched-paired GSCs (CD133 positive) and
differentiated GBM cells (DGCs; CD133 negative) from the 4121, G01, G06 and G40 lines, and found
RPA subunits RPA70 and RPA14 were preferentially expressed by GSCs (Figure 2B). To further
interrogate the role of RPA, we silenced RPA using subunit-specific lentiviral shRNAs (shRPA70,
shRPA32, shRPA14) in GSCs isolated from the G01 line (further denoted as G01-GSCs). Immunoblot
analysis revealed that silencing of any of the individual subunits negatively impacts the expression of
the other two remaining subunits (Figure 2C), suggesting that targeting of just one of the subunits is
sufficient for abrogating the overall function of total RPA. Lentivirus-mediated knockdown of RPA
subunits impaired the viability of G01-GSCs as measured by CellTiter-Glo luminiscence cell viability
assay (Figure 2D). Most importantly, RPA silencing sensitized G01-GSCs to IR (Figure 2E) and reduced
their capacity to self-renew (Figure 2F), thereby supporting our hypothesis that RPA mediates the
radio-resistant phenotype of this aggressive cell population and supported the notion that a successful
eradication of RPA function may impair their capacity to evade radio-therapy.
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Figure 2. RPA expression is crucial for the maintenance of glioblastoma cancer stem-like cells.
(A) Immunoblot analysis of RPA70, RPA32 and RPA14 in a panel of GBM primary cell lines (4121,
G01, G06, G40, G07, G16 and G20) and two normal human astrocyte cell lines (NHA33, NHA26).
β-Actin was used as a loading control. (B) Immunoblot analysis of RPA70, RPA32 and RPA14
expression in matched pairs of glioblastoma cancer stem-like cells (GSCs) and differentiated GBM cells
(DGCs) isolated from 4121, G01, G06 and G40 primary GBM cell lines. α-Tubulin or Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was used as a loading control. (C) Immunoblot analysis
validating knockdown efficiencies of lentiviral shRNAs targeting RPA70, RPA32 and RPA14 in
G01-GSCs. α-Tubulin was used as a loading control. (D) CellTiter-Glo luminescent viability assay
(Promega) of G01-GSCs transduced with lentiviral shRNA targeting RPA70, RPA32 or RPA14 assessed
72 h after virus wash. Data are presented as mean ± SD. Statistical significance was tested using
a two-way ANOVA with post-hoc Sidak’s multiple comparisons test, where *** p < 0.001. N = 3.
(E) CellTiter-Glo luminescent viability assay (Promega) of G01-GSCs transduced with lentiviral shRNA
targeting RPA70, RPA32 or RPA14 alone or 24 h after irradiation (3 Gy; COMBO) or sham-irradiated and
assessed for viability 72 h later. (E) Extreme limiting dilution assay (ELDA) of G01-GSCs transduced
with lentiviral shRNA targeting of RPA70 (2 independent shRNAs) shows significantly impaired
self-renewal of G01-GSCs after 10 days. Data are presented as mean ± SD. Statistical significance was
tested using a two-way ANOVA with post-hoc Sidak’s multiple comparisons test, where * p < 0.05,
** p < 0.01, *** p < 0.001. N = 3.
2.3. RPA70-Specific Inhibitor HAMNO Targets Glioblastoma Cancer Stem-Like Cells
RPA is involved in almost all crucial aspects of DNA metabolism and exerts its functions through
interaction with DNA as well as other proteins implicated in these processes, including ATR, Rad51,
BRCA1/2, p53 etc. [16,17]. HAMNO is a small molecular inhibitor that targets the interaction domain
of RPA70 and prevents its binding to ATR, which is indispensable for authophosphorylation events
leading to DDR activation under RS conditions [18]. First, we sought to examine whether differential
expression of RPA in matched G01-GSCs and G01-DGCs correlates with their sensitivity to HAMNO.
Indeed, G01-GSCs showed superior sensitivity to HAMNO in a dose-dependent manner (Figure 3A).
The HAMNO GI50 of G01-GSCs (33.73 µM) was nearly half of that measure for G01-DGCs (58.77 µM)
(Figure 3B). Furthermore, the exposure to HAMNO compromised the self-renewing capacity of GSCs,
as evidenced by decreased size and frequency of neurospheres formed (Figure 3C–D).
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Figure 3. RPA70-specific inhibitor 2-hydroxyanilino),methylidene]naphtalen-2-one (HAMNO) targets
glioblastoma cancer stem-like cells. (A) CellTiter-Glo luminescent viability assay (Promega) of matched
GSCs and DGCs treated with vehicle control (DMSO) or increasing doses of HAMNO—5, 10, 15, 20,
25, 50 and 100 0µM assessed at 72 h post treatment. (B) A graph showing HAMNO GI50 (72 h) in
matched GSCs and differentiated GBM cells (DGCs) assessed by CellTiter-Glo luminescent viability
assay (Promega). (C) Extreme limiting dilution assay (ELDA) in the presence of vehicle control
(DMSO) or increasing doses of HAMNO—5, 10 and 20 µM shows significantly impaired self-renewal
of GSCs 10 days after treatment. (D) Representative images of neurospheres (from three independent
experiments, day 10 post-plating) formed in the presence of vehicle control (DMSO) or increasing doses
of HAMNO—5, 10 and 20 µM. (E) Microscopy-based quantification of γH2AX foci count in GSCs after
exposure (48 h) to increasing doses of HAMNO—5, 10 and 20 µM. Data are presented as mean ± SD.
Statistical significance was tested using one-way ANOVA, where *** p < 0.001. (F) Apoptosis was
assessed by Fluorescence-Activated Cell Sorting (FACS) analysis of annexin V-positive cells. The graph
represents data from 3 independent experiments, where GSCs where treated for 36 h with increasing
doses of HAMNO—5, 10 and 20 µM or vehicle control (DMSO). (G) Apoptosis was assessed by
FACS analysis of cleaved caspase-3 -positive cells. The graph represents data from three independent
experiments, where GSCs where treated for 24 h with increasing doses of HAMNO—5, 10 and 20 µM
or vehicle control (DMSO). Data are presented as mean ± SD. N = 3. Statistical significance was tested
using Mann–Whitney Test, where * p < 0.05. (H) Viability of GSCs treated with vehicle control (DMSO)
or increasing doses of HAMNO—5, 10 and 20 µM assessed by the IncuCyte live cell analysis system
over a period of six days. Data are presented as mean ± SD. Statistical significance was tested using a
two-way ANOVA with post-hoc Sidak’s multiple comparisons test, where ** p < 0.01, *** p < 0.001.
N = 3.
To assess the impact of RPA inhibition on DSB formation using microscopy-based assay, we have
scored γH2AX foci accumulation after treating G01-GSCs with increasing concentrations of HAMNO
(Figure 3E). RPA inhibition in this experiment resulted in a dose-dependent accumulation of DSBs,
a phenomenon that correlated with an increased death of G01-GSCs by apoptosis as assessed by
annexin V and cleaved caspase-3 staining (Figure 3F–G). While 5 µM HAMNO induced significant
damage, apoptosis and negatively impacted the sphere formation, only concentrations of 10 and 20 µM
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caused a significant decrease int G01-GSCs’ viability measured by CellTiterGlo luminiscent assay over
a perior of six days (Figure 3H).
2.4. HAMNO Treatment Sensitizes Glioblastoma Cancer Stem-Like Cells to Ionizing Radiation
GSCs evade DNA damaging therapies by preferential DDR activation [6,9,19]. We observed that
HAMNO treatment alone induced DSBs in GSCs, resulting in apoptosis. Thus, we hypothesized that
such a challenge can sensitize these aggressive cells to IR. Upon exposure to HAMNO (24 h) or a vehicle
control (DMSO), we irradiated G01-GSCs with 3 Gy or sham-irradiated and measured γH2AX foci
counts 24 h later. The combination of HAMNO and IR was more effective at inducing DNA damage
(irrespective of dose) compared to either of the monotherapies alone (Figure 4A–D). An increase in
DNA damage led to cell cycle checkpoint activation, as evidenced by reduced proliferative (% of
actively proliferating S phase cells; Figure 4E–G) and mitotic indexes (% of mitotic cells; Figure 5A–C).
This combinational impact on cell cycle checkpoints translated into significant decrease in cell survival,
where G01-GSCs treated with IR or HAMNO (5 or 10 µM) exhibited better survival than those exposed
to their combination (Figure 5D–F).
Figure 4. HAMNO treatment induces DNA damage and activates cell cycle checkpoints in glioblastoma
cancer stem-like cells. (A) Representative confocal microscopy images of γH2AX foci in G01-GSCs
treated for 24 h with a vehicle control (DMSO) or increasing doses of HAMNO—5, 10 and 20 µM; then
irradiated (COMBO) or sham-irradiated and incubated for an additional 24 h. (B–D) Microscopy-based
quantification of γH2AX foci in G01-GSCs treated for 24 h with a vehicle control (DMSO) or increasing
doses of HAMNO—5, 10 and 20 µM; then irradiated (COMBO) or sham-irradiated and incubated for
additional 24 h. (E–G) Microscopy-based quantification of a proliferative index (% of nuclear cyclin
A-positive cells) in G01-GSCs treated for 24 h with a vehicle control (DMSO) or increasing doses of
HAMNO—5, 10 and 20 µM; then irradiated (COMBO) or sham-irradiated and incubated for additional
24 h. Data are presented as mean ± SD. Statistical significance was tested using one-way ANOVA,
where ** p < 0.01, *** p < 0.001. N = 3.
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Figure 5. HAMNO treatment lowers the mitotic index and sensitizes glioblastoma cancer stem-like
cells to ionizing radiation. (A–B) Microscopy-based quantification of a mitotic index (% of cells in
mitosis) in G01-GSCs treated for 24 h with a vehicle control (DMSO) or increasing doses of HAMNO—5,
10 and 20 µM; then irradiated (COMBO) or sham-irradiated and incubated for additional 24 h. Data
are presented as mean ± SD. Statistical significance was tested using one-way ANOVA test, where
* p < 0.05, ** p < 0.01, *** p < 0.001; ns = not significant. N = 3. (D–E) CellTiter-Glo luminescent viability
assay (Promega) of G01-GSCs treated for 24 h with a vehicle control (DMSO) or increasing doses of
HAMNO—5, 10 and 20 µM; then irradiated (COMBO) or sham-irradiated and incubated for additional
48 h. Data are presented as mean ± SD. Statistical significance was tested using a two-way ANOVA
with post-hoc Sidak’s multiple comparisons test, where * p < 0.01, ** p < 0.01, *** p < 0.001. ns = not
significant. N = 3.
3. Discussion
Single-stranded DNA (ssDNA) is perhaps one of the most ubiquitous and important biological
intermediates formed throughout the life of cells [20,21]. Genomes of cells are under continous attack
by exogenous and endogenous factors resulting in DNA damage, which, if left unrepaired, leads
to genomic instability. RPA, a heterotrimeric ssDNA-binding protein, is required for each of the
three major DNA repair pathways: nucleotide excision repair (NER), base excision repair (BER), and
DSBs repair [3,4]. Due to its extensive involvement in safeguarding genomic stability, RPA has been
shown to tightly associate with carcinogenesis. An early study aiming to identify autoantigens in
breast cancer patients showed that antibodies against RPA32 can be detected prior to diagnosis [22].
In hepatocellular carcinoma and gastric cancer, higher RPA14 expression was found to correlate with a
poor outcome [23,24]. Another study in bladder cancer showed that while in early stage low RPA32
levels positively correlated with patient outcome, at later stages in invasive tumors, both high RPA70
and RPA32 expression informed adverse prognosis [25]. Our study shows that high expression of all
three RPA subunits, RPA70, RPA32 and RPA14, positively correlates with WHO malignancy stage and
informs poor glioma patient survival.
Radiation therapy, which represents a standard-of-care for GBM patients, aims to eradicate cancer
cells by inducing a broad viariety of DNA lesions, among those DSBs being reportedly the most
detrimental in regards to maintaining genomic stability [20]. Here, we sought to interrogate the role of
RPA in the radio-resistance of GBM and GSCs. We show that RPA expression is higher in GSCs than in
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DGCs. This is expected as our previous work has shown that GSCs are highly proliferative and exhibit
greater ROS production compared to DGCs, which translates in higher number of ssDNA breaks and
oxidative DNA lesions [15,19]. Because the key feature that distinguished tumor cells from most normal
cells is their sustained proliferation, DNA replication has been harnessed as a semi-selective target in
cancer therapies for decades [1,2,20]. Prior to the discovery of RPA inhibitors, inhibitors of RPA-ssDNA
interaction have been shown to synergize with cisplatin, displaying potential for its therapeutic
targeting [18]. The HAMNO inhibitor prevents RPA70’s interaction with ATR and so inhibits the
activation of DDR in response to RS. The inhibitory effect of HAMNO was reportedly enhanced
when combined with etoposide, a topoisomerase 1A inhibitor that induces RS [18]. Since gliomas
and GSCs have been reported to undergo a constitutive RS, we speculated that HAMNO-mediated
inhibition of RPA in GSCs would render this cell population sensitive to radiotherapy. Indeed, our
study provides the evidence that RPA inhibition significantly impairs maintenance and survival of
GSCs as monotherapy, an effect that is further potentiate by irradiation. The dose-dependent induction
of DSBs after HAMNO treatment drives the GSCs into apoptosis.
Bélanger et al. (2018) reported that RPA exhaustion represents a major determinant of cisplatin
sensitivity in ovarian cancer cell lines, a finding that harbors an important implication toward improving
therapy of various cancers that initially respond to platinum-based agents but later relapse due to
intrinsic or acquired drug resistance [26]. Wang et al. (2018) showed that RPA70 promotes tumor
proliferation via CDK4/Cyclin-D pathway [27]. Toledo et al. (2013) showed that RPA depletion
in cells under RS conditions triggers the activation of irreversible cell-cycle arrest and suggested
that RPA-exhaustion-associated mitotic catastrophe might be a promising target in future cancer
therapies [28]. In our model, targeting RPA reduces the proliferative index and prevents entry into
mitosis, which is concordant with the studies mentioned above.
In cancer treatment, radiation therapy is second only to surgery in terms of its curative potential [12].
However, many cancers including GBM exhibit evasive radio-resistance, stressing the urgent need for
identification and validation of putative radio-sensitizers. Here, we uncovered a novel role for RPA in
the maintenance and radio-resistance of GSCs, thereby supporting its potential clinical significance as
a biomarker in GBM.
4. Methodology
4.1. Tumor Dissociation, Cell Culture and MACS Sorting
GBM primary cells numbering 4121 in total were a generous gift of Prof. J.N. Rich (UCSD, CA,
USA). Primary GBM cell lines (G01, G06, G40, G07, G16, G20; see Table S3) were derived from GBM
(WHO grade IV glioma) tissue biopsies obtained at surgery after signing an informed consent as
outlined by the Regional Danish Ethical Committee/Danish Data Protection Agency (protocol no.:
H-3-2009-136_63114). Primary GBM cell lines were maintained as subcutaneous patient-derived
xenografts by direct subcutaneous (SC) implantation of tissue biopsy chunks into the flanks of
immunocompromised NOD.Cg-Prkdcscid (Taconic Biosciences, Inc. Rensselaer, New York, NY, USA,
cat.no. NOG-F). This protocol was approved by the Danish Welfare Law on Animal Experiments Act
no 1306 (protocol no.: 2012-15-2934-00636/2018-15-0201-01391).
For in vitro experiments, resected SC tumors were dissociated using a Papain Dissociation Kit
according to manufacturer’s instructions (Worthington Biochemical Corporation, Lakewood, New
Jersey, USA cat.no. LK003150) and maintained as neurosphere cultures in neurobasal–A medium
(Invitrogen, Carlsbad, CA, USA, cat.no. 12349-015,) supplemented with B27 minus Vitamin A
(Invitrogen, Carlsbad, CA, USA, cat.no. 12587-010), Epidermal Growth Factor (EGF) (20 ng/mL) (R&D
systems, Minneapolis, MN, USA, cat.no 236-EG-01M), Fibroblast Growth Factor (FGF) (20 ng/mL)
(R&D systems, Minneapolis, MN, USA, cat.no. 4114-TC-01M), GlutaMax (Invitrogen, Carlsbad, CA,
USA, cat.no. 35050-038) and antibiotics (Invitrogen, Carlsbad, CA, USA, cat.no. 15140-122). Cells were
allowed to recover for 24 h prior their use for downstream experiments. Matched GBM cancer stem-like
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cells (GSCs; CD133+) and their differentiated counterpart populations (DGCs; CD133-) were isolated by
magnetic (MACS) sorting using a CD133 microbeads kit (Miltenyi Biotec, Bergisch Gladbach, Germany,
cat.no. 130-100-857). The GSCs were maintained in neurobasal–A medium, whilst the DGCs were
maintained as monolayer in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen, Carlsbad, CA,
USA, cat.no. 31966-021), supplemented with 10% Fetal Bovine Serum (FBS) (Invitrogen, Carlsbad, CA,
USA, cat.no. 26140095) and antibiotics (Invitrogen, Carlsbad, CA, USA, cat.no. 15140-122) as reported
previously [14]. Both populations were validated functionally by sphere forming capacity and the
expression of stem cell markers by immunoblotting for expression of SOX2 and GFAP.
HEK293T cells obtained from American Type Culture Collection (ATCC) were maintained a
monolayer in DMEM (Invitrogen, Carlsbad, CA, USA, cat.no. 31966-021), supplemented with 10% FBS
(Invitrogen, Carlsbad, CA, USA, cat.no. 26140095) and antibiotics (Invitrogen, Carlsbad, CA, USA,
cat.no. 15140-122). For microscopy-based studies, cells were seeded on Geltrex (Invitrogen, Carlsbad,
CA, USA, cat.no. 14113-202) coated plates.
Normal human astrocytes (NHA33, NHA26) obtained from ATCC were maintained in a monolayer
in Astrocyte Medium (ScienCell Research Laboratories, Carlsbad, CA, USA, cat.no. SC-1801).
4.2. Flow Cytometry Analysis of Apoptosis
To measure early apoptosis, single cells were incubated with annexin V-Fluorescein (FITC) (dead
cell apoptosis kit; BD biosciences, Franklin Lakes, NJ, USA, cat.no. V13242,) and processed according
to the manufacturer’s instructions. For staining of cleaved caspase-3, cells were fixed for 30 min in
ice-cold 96% ethanol, permeabilized using 0.25% Triton-X (Sigma-Aldrich, St. Louis, MI, USA, cat.no.
T9284) and stained for 2 h with cleaved caspase-3 alexa flour 488 conjugated antibody (Cell Signaling,
Danvers, Massachusetts, cat.no. 9669S,). All FACS flow cytometry samples were run on BD’s FACS
Verse (BD biosciences, Franklin Lakes, NJ, USA) and analyzed using the FlowJo software version 10
(BD biosciences, Franklin Lakes, NJ, USA).
4.3. Drug Preparation and Irradiation
HAMNO was obtained from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MI, USA, Cat.no.
SML1234-5MG). Drug stock solutions were made in Dimethyl sulfoxide (DMSO) (Sigma-Aldrich,
St. Louis, MI, USA, cat.no. D8418) at 30 µM and stored at −80 ◦C in dark and diluted fresh in the
culture medium immediately before use.
For IR studies, cells were seeded on Geltrex (Invitrogen, Carlsbad, CA, USA, cat.no. 14113-202)
coated plates in 96- or six-well format and induced with DSBs using YXLON smart (YXLON International
A/S, Hamburg, Germany) at a rate of 0.04 Gy/s.
4.4. Proliferation Assay
For real-time analysis of cell proliferation over several days, the IncuCyte Zoom System (Essen
BioScience Inc., Ann Arbor, MI, USA) was utilized. In brief, cells were seeded at a starting density of
3500 cells/well. After overnight recovery, cells were treated with appropriate doses of HAMNO and IR
before incubation in the IncuCyte Zoom Live cell analysis system. Cell images were collected from
four separate positions every four hours. For analysis, well confluency was exported.
4.5. Lentiviral Particle Preparation
The preparation of lentiviral particles and viral transduction was performed as described
previously [1,2,29]. In brief, HEK293T cells were co-transfected with second generation packaging
plasmids VSV and PAX and pLKO plasmids (RPA70 (Sigma-Aldrich, St. Louis, MI, USA,
TRCN0000010983/TRCN00000318752), RPA32 (Sigma-Aldrich, St. Louis, MI, USA, TRCN00000231920)
and RPA14 (Sigma-Aldrich, St. Louis, MI, USA, TRCN0000018861) using a calcium phosphate
transfection kit (Takara Bio USA, Inc. Mountain View, CA, USA, cat.no. 631312). All viral particles were
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concentrated using PolyEthylene Glycol (PEG)-it virus precipitation solution (SBI, System Biosciences,
Palo Alto, CA, USA, cat.no. LV810A-1) and stored in aliquots at −80 ◦C for later use.
4.6. Cell Viability
For cell viability dissociated cells were seeded at a density of 3500 cells/well in 100 ul of media in
96-well plates. Cell viability was measured at indicated time points using the CellTiter-Glo luminescent
cell viability assay (Promega, Madison, WI, USA, cat.no. G7571,) according to the manufacturer’s
instructions or assessed using the IncuCyte Life cell analysis system (EssenBioscience Inc., Ann Arbor,
MI, USA). Results were analysed using Microsoft Excel and GraphPad Prism software version 8
(GraphPad Software, San Diego, CA, USA).
4.7. Neurosphere Formation and Extreme Limiting Dilution Assay (ELDA)
For neurosphere formation single cells were plated at a density of 2000 cells/mL in 2ml of complete
media in six-well plates. After 7–10 days, plates were observed for sphere formation. For ELDA
cells were seeded at a density of 25, 50, 250, 500 and 750 cells per well in 96-wells. The frequency of
neurosphere formation (surrogated for self-renewal) was evaluated 10 days after exposure to HAMNO
or transduction with shRNA targeting RPA70. Wells were scored positive or negative for the presence
of at least one neurosphere. The estimated stem cell frequency was calculated using extreme limiting
dilution analysis as reported previously [30].
4.8. Immunoblotting
Protein extracts were prepared using whole lysis buffer (WLB; 50 mM Tris–HCl (Trizma Base;
Sigma-Aldrich, St. Louis, MI, USA, cat.no. 93350. HCl; Sigma-Aldrich, St. Louis, MI, USA,
cat.no. H1758), 10% Glycerol (Sigma-Aldrich, St. Louis, MI, USA, cat.no. G5516), 2% SDS (Bio-Rad
Laboratories, Inc., Hercules, CA, USA, cat.no. 161-0418-MSDS) and water) and protein concentrations
were determined by Pierce BCA Protein Assay (Thermo Fisher Scientific, Waltham, MA, USA, cat.no.
23227,). Cell lysates (25–30 µg) were separated by electrophoresis on SDS-PAGE gels (Bio-Rad
Laboratories, Inc., Hercules, CA, USA). Proteins were transferred onto nitrocellulose membranes using
the trans-blot turbo transfer system (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and incubated
with appropriate primary antibodies: RPA14 (Abcam, Cambridge, UK, cat.no. ab97436,); RPA32
(Abcam, Cambridge, UK, cat.no. ab2175); RPA70 (Abcam, Cambridge, UK, cat.no. ab79398); SOX2
(Merck Millipore, Burlington, MA, USA, cat.no. MAB4343); Glial Fibrillary Acidic Protein (GFAP)
(Agilent Dako, Santa Clara, CA, USA, cat.no. Z0334); α-Tubulin (Sigma-Aldrich, St. Louis, MI, USA,
cat.no. T9026-0.2ML); GAPDH (GeneTex, Irvine, CA, USA, cat.no. GT239); β-actin (Santa Cruz
Biotechnologies, Dallas, TX, USA, cat.no. SC-47778) and species-specific secondary antibodies: HRP
goat anti-rabbit IgG antibody (Vector Laboratories Inc, Burlingame, CA, USA, cat.no. PI-1000,) and
HRP horse anti-mouse IgG antibody (Vector Laboratories Inc, Burlingame, CA, USA, cat.no. PI-2000).
Amersham ECL prime western blotting detection reagent (GE Healthcare, Chicago, IL, USA, cat.no.
RPN2232,) was used for detection using Image Lab software version 5.0 (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA).
4.9. Immunofluorescence and Image Analysis
For immunofluorescence staining, cells grown on geltrex-coated coverslips (Invitrogen, Carlsbad,
CA, USA, cat.no. 14113-202) and fixed with 4% paraformaldehyde (PFA) (Sigma-Aldrich, St. Louis,
MI, USA, cat.no. P6148), permeabilized using 0.25% Triton-X (Sigma-Aldrich, St. Louis, MI, USA,
cat.no. T9284) followed by blocking for 30 min in 10% Bovine Serum Albumin (BSA) (Bovine Albumin
Fraction V, 7.5% solution; Thermo Fisher Scientific, Waltham, MA, USA, cat.no. 15260037). Cells were
incubated with respective primary antibodies (H2AX (Ser139) (Merck Millipore, Burlington, MA, USA,
cat.no. 05-636); Cyclin A (H-432) (Santa Cruz Biotechnologies, Dallas, TX, USA, cat.no. sc-751) in 2%
BSA (Bovine Albumin Fraction V, 7.5% solution; Thermo Fisher Scientific, Waltham, Massachusetts,
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cat.no. 15260037) for 2 h followed by incubation with appropriate secondary conjugated antibodies
(Alexa Flour 488 (Invitrogen, Carlsbad, CA, USA, cat.no. A11029); Alexa Flour 568 (Invitrogen,
Carlsbad, CA, USA, cat.no. A11036). Nuclei were counterstained with 4,6-Diamidino-2-Phenylindole
(DAPI) (Sigma-Aldrich, St. Louis, MI, USA, cat.no. D9542-10MG). Automated imaging and analysis
were performed using Olympus Scan-R screening station equipped with Scan-R analysis software as
described previously [29].
4.10. In Silico Analysis of Public Data Sets
The expression of RPA70, RPA32 and RPA14 mRNA in normal brain, malignant gliomas
(WHO grade II III and IV) and its correlation patient survival (Kaplan-Meier survival analysis)
was performed using publically available microarray expression data sets (REMBRANDT, TCGA_GBM
and TCGA_GBMLGG) via the gliovios platform: http://gliovis.bioinfo.cnio.es/ [14]. The multivariate
Cox proportional hazard analysis was performed using the coxph() function from the “survival”
R package using log2 transformed microarray expression data [31]. For the coxph regression the
REMBRANDT data were trimmed to exclude patients where histology or WHO grade are not available.
4.11. Statistical Analysis
All statistical analyses were performed using GraphPad Prism 7 software or R 3.6.1. Statistical
significance was assessed by the unpaired t-test or two-way ANOVA as indicated. Precise details on
statistical tests can be found in the figure legends. p-values <0.05 were considered to be significant.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/5/1588/s1;
Figure S1. Figure providing supplementary information to main Figure 1. Figure S2. Figure providing
supplementary information to main Figure 1. Table S1. A multi-variate Cox proportional hazard analysis—
REMBRANDT data set. Table S2. A multi-variate Cox proportional hazard analysis—TCGA data sets. Table S3.
Primary GBM cell lines characteristics.
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